Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Influenza

  Free Subscription


Articles published in Antiviral Res

Retrieve available abstracts of 84 articles:
HTML format
Text format



Single Articles


    July 2018
  1. SCHRADER T, Dudek SE, Schreiber A, Ehrhardt C, et al
    The clinically approved MEK inhibitor Trametinib efficiently blocks influenza A virus propagation and cytokine expression.
    Antiviral Res. 2018 Jul 7. pii: S0166-3542(18)30364.
    PubMed     Text format     Abstract available


  2. LACKENBY A, Besselaar TG, Daniels RS, Fry A, et al
    Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors and status of novel antivirals, 2016-2017.
    Antiviral Res. 2018;157:38-46.
    PubMed     Text format     Abstract available


    June 2018
  3. LA FRAZIA S, Piacentini S, Riccio A, Rossignol JF, et al
    The second-generation thiazolide haloxanide is a potent inhibitor of avian influenza virus replication.
    Antiviral Res. 2018 Jun 13. pii: S0166-3542(18)30079.
    PubMed     Text format     Abstract available


  4. KO EJ, Lee Y, Lee YT, Kim YJ, et al
    MPL and CpG combination adjuvants promote homologous and heterosubtypic cross protection of inactivated split influenza virus vaccine.
    Antiviral Res. 2018 Jun 6. pii: S0166-3542(18)30007.
    PubMed     Text format     Abstract available


    March 2018
  5. MATOS AR, Resende PC, Miranda MD, Garcia CC, et al
    Susceptibility of Brazilian influenza A(H1N1)pdm09 viruses to neuraminidase inhibitors in the 2014-2016 seasons: Identification of strains bearing mutations associated with reduced inhibition profile.
    Antiviral Res. 2018 Mar 27. pii: S0166-3542(17)30768.
    PubMed     Text format     Abstract available


  6. MCKIMM-BRESCHKIN JL, Barrett S, Wong FYK, Pudjiatmoko, et al
    Identification of Indonesian clade 2.1 highly pathogenic influenza A(H5N1) viruses with N294S and S246N neuraminidase substitutions which further reduce oseltamivir susceptibility.
    Antiviral Res. 2018;153:95-100.
    PubMed     Text format     Abstract available


  7. MALCOLM BA, Aerts CA, Dubois KJ, Geurts FJ, et al
    PrEP-001 prophylactic effect against rhinovirus and influenza virus - RESULTS of 2 randomized trials.
    Antiviral Res. 2018;153:70-77.
    PubMed     Text format     Abstract available


  8. MUSHARRAFIEH R, Ma C, Wang J
    Profiling the in vitro drug-resistance mechanism of influenza A viruses towards the AM2-S31N proton channel blockers.
    Antiviral Res. 2018 Mar 5. pii: S0166-3542(18)30065.
    PubMed     Text format     Abstract available


  9. GU H, Gao Y, Zhou S, Sun F, et al
    Bivalent vaccine platform based on ca influenza virus vaccine elicits protective immunity against human adenoviruses.
    Antiviral Res. 2018 Mar 1. pii: S0166-3542(17)30305.
    PubMed     Text format     Abstract available


    January 2018
  10. HUI DS, Lee N, Chan PK, Beigel JH, et al
    The role of adjuvant immunomodulatory agents for treatment of severe influenza.
    Antiviral Res. 2018;150:202-216.
    PubMed     Text format     Abstract available


    October 2017
  11. MARATHE BM, Mostafa HH, Vogel P, Pascua PNQ, et al
    A pharmacologically immunosuppressed mouse model for assessing influenza B virus pathogenicity and oseltamivir treatment.
    Antiviral Res. 2017 Oct 31. pii: S0166-3542(17)30491.
    PubMed     Text format     Abstract available


  12. SARVESTANI ST, McAuley JL
    The role of the NLRP3 inflammasome in regulation of antiviral responses to influenza A virus infection.
    Antiviral Res. 2017 Oct 30. pii: S0166-3542(17)30611.
    PubMed     Text format     Abstract available


  13. KIM MC, Lee YN, Kim YJ, Choi HJ, et al
    Immunogenicity and efficacy of replication-competent recombinant influenza virus carrying multimeric M2 extracellular domains in a chimeric hemagglutinin conjugate.
    Antiviral Res. 2017;148:43-52.
    PubMed     Text format     Abstract available


  14. GORDON NA, McGuire KL, Wallentine SK, Mohl GA, et al
    Divalent copper complexes as influenza A M2 inhibitors.
    Antiviral Res. 2017;147:100-106.
    PubMed     Text format     Abstract available


  15. TILMANIS D, van Baalen C, Oh DY, Rossignol JF, et al
    The susceptibility of circulating human influenza viruses to tizoxanide, the active metabolite of nitazoxanide.
    Antiviral Res. 2017 Oct 3. pii: S0166-3542(17)30546.
    PubMed     Text format     Abstract available


    September 2017
  16. WU Y, Yang D, Xu B, Liang W, et al
    Immune efficacy of an adenoviral vector-based swine influenza vaccine against antigenically distinct H1N1 strains in mice.
    Antiviral Res. 2017 Sep 20. pii: S0166-3542(17)30180.
    PubMed     Text format     Abstract available


    August 2017
  17. GUBAREVA LV, Besselaar TG, Daniels RS, Fry A, et al
    Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2015-2016.
    Antiviral Res. 2017 Aug 9. pii: S0166-3542(17)30267.
    PubMed     Text format     Abstract available


  18. PICHON M, Gaymard A, Josset L, Valette M, et al
    Characterization of oseltamivir-resistant influenza virus populations in immunosuppressed patients using digital-droplet PCR: Comparison with qPCR and next generation sequencing analysis.
    Antiviral Res. 2017 Aug 2. pii: S0166-3542(17)30431.
    PubMed     Text format     Abstract available


  19. HU Y, Zhang J, Musharrafieh RG, Ma C, et al
    Discovery of dapivirine, a nonnucleoside HIV-1 reverse transcriptase inhibitor, as a broad-spectrum antiviral against both influenza A and B viruses.
    Antiviral Res. 2017;145:103-113.
    PubMed     Text format     Abstract available


  20. ZHANG S, Sun F, Ren T, Duan Y, et al
    Immunogenicity of an influenza virus-vectored vaccine carrying the hepatitis C virus protein epitopes in mice.
    Antiviral Res. 2017 Aug 1. pii: S0166-3542(16)30742.
    PubMed     Text format     Abstract available


    June 2017
  21. PAUL SS, Mok CK, Mak TM, Ng OW, et al
    A cross-clade H5N1 influenza A virus neutralizing monoclonal antibody binds to a novel epitope within the vestigial esterase domain of hemagglutinin.
    Antiviral Res. 2017 Jun 17. pii: S0166-3542(17)30042.
    PubMed     Text format     Abstract available


  22. LIU M, Lo EC, Wang G, Chow HF, et al
    Identification of influenza polymerase inhibitors targeting polymerase PB2 cap-binding domain through virtual screening.
    Antiviral Res. 2017 Jun 16. pii: S0166-3542(16)30584.
    PubMed     Text format     Abstract available


  23. PETROVA NV, Emelyanova AG, Gorbunov EA, Edwards MR, et al
    Efficacy of novel antibody-based drugs against rhinovirus infection: In vitro and in vivo results.
    Antiviral Res. 2017;142:185-192.
    PubMed     Text format     Abstract available


    May 2017
  24. GIAROLA-SILVA S, Coelho-Dos-Reis JGA, Mourao MM, Campi-Azevedo AC, et al
    Distinct patterns of cellular immune response elicited by influenza non-adjuvanted and AS03-adjuvanted monovalent H1N1(pdm09) vaccine.
    Antiviral Res. 2017;144:70-82.
    PubMed     Text format     Abstract available


  25. LEE N, Wong CK, Chan MCW, Yeung ESL, et al
    Anti-inflammatory effects of adjunctive macrolide treatment in adults hospitalized with influenza: A randomized controlled trial.
    Antiviral Res. 2017 May 20. pii: S0166-3542(17)30141.
    PubMed     Text format     Abstract available


  26. COURTIN N, Fotso AF, Fautrad P, Mas F, et al
    Antiviral activity of formyl peptide receptor 2 antagonists against influenza viruses.
    Antiviral Res. 2017;143:252-261.
    PubMed     Text format     Abstract available


    April 2017
  27. LIU JX, Zhang Y, Hu QP, Li JQ, et al
    Anti-inflammatory effects of rosmarinic acid-4-O-beta-D-glucoside in reducing acute lung injury in mice infected with influenza virus.
    Antiviral Res. 2017 Apr 28. pii: S0166-3542(16)30454.
    PubMed     Text format     Abstract available


  28. WANG M, Wang S, Wang W, Wang Y, et al
    Inhibition effects of novel polyketide compound PPQ-B against influenza A virus replication by interfering with the cellular EGFR pathway.
    Antiviral Res. 2017;143:74-84.
    PubMed     Text format     Abstract available


  29. WANG Y, Wu J, Xue C, Wu Z, et al
    A recombinant H7N9 influenza vaccine with the H7 hemagglutinin transmembrane domain replaced by the H3 domain induces increased cross-reactive antibodies and improved interclade protection in mice.
    Antiviral Res. 2017 Apr 10. pii: S0166-3542(16)30791.
    PubMed     Text format     Abstract available


  30. HAASBACH E, Muller C, Ehrhardt C, Schreiber A, et al
    The MEK-inhibitor CI-1040 displays a broad anti-influenza activity in vitro and provides a prolonged treatment window compared to standard of care in vivo.
    Antiviral Res. 2017 Apr 1. pii: S0166-3542(17)30060.
    PubMed     Text format     Abstract available


  31. YANG JR, Cheng CY, Chen CY, Lin CH, et al
    A virus-like particle vaccination strategy expands its tolerance to H3N2 antigenic drift by enhancing neutralizing antibodies against hemagglutinin stalk.
    Antiviral Res. 2017;140:62-75.
    PubMed     Text format     Abstract available


  32. ALBULESCU L, Bigay J, Biswas B, Weber-Boyvat M, et al
    Uncovering oxysterol-binding protein (OSBP) as a target of the anti-enteroviral compound TTP-8307.
    Antiviral Res. 2017;140:37-44.
    PubMed     Text format     Abstract available


    March 2017
  33. LEYVA-GRADO VH, Palese P
    Aerosol administration increases the efficacy of oseltamivir for the treatment of mice infected with influenza viruses.
    Antiviral Res. 2017;142:12-15.
    PubMed     Text format     Abstract available


    February 2017
  34. PENDZIALEK J, Roose K, Smet A, Schepens B, et al
    Bispecific T-Cell engaging antibody constructs targeting a universally conserved part of the viral M2 ectodomain cure and prevent influenza A virus infection.
    Antiviral Res. 2017 Feb 28. pii: S0166-3542(16)30618.
    PubMed     Text format     Abstract available


  35. GAO L, Han J, Si J, Wang J, et al
    Cryptoporic acid E from Cryptoporus volvatus inhibits influenza virus replication in vitro.
    Antiviral Res. 2017 Feb 20. pii: S0166-3542(16)30540.
    PubMed     Text format     Abstract available


  36. COLEMAN BL, Hassan K, Green K, Gubbay JB, et al
    Pre-and post-pandemic trends in antiviral use in hospitalized patients with laboratory-confirmed influenza: 2004/05-2013/14, Toronto, Canada.
    Antiviral Res. 2017 Feb 5. pii: S0166-3542(16)30612.
    PubMed     Text format     Abstract available


  37. TAO W, Hurst B, Shakya AK, Uddin MJ, et al
    Consensus M2e peptide conjugated to gold nanoparticles confers protection against H1N1, H3N2 and H5N1 influenza A viruses.
    Antiviral Res. 2017 Feb 1. pii: S0166-3542(16)30409.
    PubMed     Text format     Abstract available


    January 2017
  38. HU Y, Musharrafieh R, Ma C, Zhang J, et al
    An M2-V27A channel blocker demonstrates potent in vitro and in vivo antiviral activities against amantadine-sensitive and -resistant influenza A viruses.
    Antiviral Res. 2017 Jan 10. pii: S0166-3542(16)30522.
    PubMed     Text format     Abstract available


  39. TELCIAN AG, Zdrenghea MT, Edwards MR, Laza-Stanca V, et al
    Vitamin D increases the antiviral activity of bronchial epithelial cells in vitro.
    Antiviral Res. 2017;137:93-101.
    PubMed     Text format     Abstract available


    December 2016
  40. KOBAYASHI M, Kodama M, Noshi T, Yoshida R, et al
    Therapeutic efficacy of peramivir against H5N1 highly pathogenic avian influenza viruses harboring the neuraminidase H275Y mutation.
    Antiviral Res. 2016 Dec 21. pii: S0166-3542(16)30327.
    PubMed     Text format     Abstract available


    November 2016
  41. YANG WT, Yang GL, Wang Q, Huang HB, et al
    Protective efficacy of Fc targeting conserved influenza virus M2e antigen expressed by Lactobacillus plantarum.
    Antiviral Res. 2016 Nov 28. pii: S0166-3542(16)30462.
    PubMed     Text format     Abstract available


  42. YUAN S, Chu H, Ye J, Singh K, et al
    Identification of a novel small-molecule compound targeting the influenza A virus polymerase PB1-PB2 interface.
    Antiviral Res. 2016 Nov 10. pii: S0166-3542(16)30372.
    PubMed     Text format     Abstract available


  43. TU V, Abed Y, Barbeau X, Carbonneau J, et al
    The I427T neuraminidase (NA) substitution, located outside the NA active site of an influenza A(H1N1)pdm09 variant with reduced susceptibility to NA inhibitors, alters NA properties and impairs viral fitness.
    Antiviral Res. 2016;137:6-13.
    PubMed     Text format     Abstract available


    October 2016
  44. SMEE DF, Barnard DL, Jones SM
    Activities of JNJ63623872 and oseltamivir against influenza A H1N1pdm and H3N2 virus infections in mice.
    Antiviral Res. 2016 Oct 19. pii: S0166-3542(16)30404.
    PubMed     Text format     Abstract available


  45. WILSON JR, Guo Z, Reber A, Kamal RP, et al
    An influenza A virus (H7N9) anti-neuraminidase monoclonal antibody with prophylactic and therapeutic activity in vivo.
    Antiviral Res. 2016 Oct 3. pii: S0166-3542(16)30341.
    PubMed     Text format     Abstract available


    August 2016
  46. YATES PJ, Raimonde DS, Zhao HH, Man CY, et al
    Phenotypic and genotypic analysis of influenza viruses isolated from adult subjects during a phase II study of intravenous zanamivir in hospitalised subjects.
    Antiviral Res. 2016 Aug 25. pii: S0166-3542(16)30463.
    PubMed     Text format     Abstract available


  47. JANG Y, Lee HW, Shin JS, Go YY, et al
    Antiviral activity of KR-23502 targeting nuclear export of influenza B virus ribonucleoproteins.
    Antiviral Res. 2016 Aug 23. pii: S0166-3542(16)30206.
    PubMed     Text format     Abstract available


  48. LEMESSURIER KS, Lin Y, McCullers JA, Samarasinghe AE, et al
    Antimicrobial peptides alter early immune response to influenza A virus infection in C57BL/6 mice.
    Antiviral Res. 2016 Aug 13. pii: S0166-3542(16)30296.
    PubMed     Text format     Abstract available


  49. VOLLMER AH, Gebre MS, Barnard DL
    Serum amyloid A (SAA) is an early biomarker of influenza virus disease in BALB/c, C57BL/2, Swiss-Webster, and DBA.2 mice.
    Antiviral Res. 2016 Aug 11. pii: S0166-3542(16)30131.
    PubMed     Text format     Abstract available


  50. PIETRZAK M, Maciola A, Zdanowski K, Protas-Kulkowska AM, et al
    An avian influenza H5N1 virus vaccine candidate based on the extracellular domain produced in yeast system as subviral particles protects chickens from lethal challenge.
    Antiviral Res. 2016 Aug 3. pii: S0166-3542(16)30215.
    PubMed     Text format     Abstract available


  51. LIU WC, Liu YY, Chen TH, Liu CC, et al
    Multi-subtype influenza virus-like particles incorporated with flagellin and granulocyte-macrophage colony-stimulating factor for vaccine design.
    Antiviral Res. 2016;133:110-118.
    PubMed     Text format     Abstract available


    July 2016
  52. MA C, Li F, Musharrafieh R, Wang J, et al
    Discovery of cyclosporine A and its analogs as broad-spectrum anti-influenza drugs with a high in vitro genetic barrier of drug resistance.
    Antiviral Res. 2016 Jul 28. pii: S0166-3542(16)30148.
    PubMed     Text format     Abstract available


  53. CAI W, Chen S, Li Y, Zhang A, et al
    14-deoxy-11,12-didehydroandrographolide attenuates excessive inflammatory responses and protects mice lethally challenged with highly pathogenic A(H5N1) influenza viruses.
    Antiviral Res. 2016 Jul 27. pii: S0166-3542(16)30072.
    PubMed     Text format     Abstract available


  54. FU Y, Gaelings L, Soderholm S, Belanov S, et al
    JNJ872 inhibits influenza A virus replication without altering cellular antiviral responses.
    Antiviral Res. 2016;133:23-31.
    PubMed     Text format     Abstract available


  55. DAWOOD FS, Jara J, Gonzalez R, Castillo JM, et al
    A randomized, double-blind, placebo-controlled trial evaluating the safety of early oseltamivir treatment among children 0-9 years of age hospitalized with influenza in El Salvador and Panama.
    Antiviral Res. 2016 Jul 20. pii: S0166-3542(16)30221.
    PubMed     Text format     Abstract available


    June 2016
  56. TAKASHITA E, Ejima M, Ogawa R, Fujisaki S, et al
    Antiviral susceptibility of influenza viruses isolated from patients pre- and post-administration of favipiravir.
    Antiviral Res. 2016 Jun 16. pii: S0166-3542(16)30338.
    PubMed     Text format     Abstract available


  57. HURT AC, Besselaar TG, Daniels RS, Ermetal B, et al
    Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2014-2015.
    Antiviral Res. 2016 Jun 2. pii: S0166-3542(16)30216.
    PubMed     Text format     Abstract available


    May 2016
  58. ALJURAYYAN AN, Sharma R, Upile N, Beer H, et al
    A critical role of T follicular helper cells in human mucosal anti-influenza response that can be enhanced by immunological adjuvant CpG-DNA.
    Antiviral Res. 2016 May 28. pii: S0166-3542(16)30129.
    PubMed     Text format     Abstract available


  59. ABED Y, Bouhy X, L'Huillier AG, Rheaume C, et al
    The E119D neuraminidase mutation identified in a multidrug-resistant influenza A(H1N1)pdm09 isolate severely alters viral fitness in vitro and in animal models.
    Antiviral Res. 2016 May 13. pii: S0166-3542(16)30161.
    PubMed     Text format     Abstract available


    February 2016
  60. YAMADA H, Nagase S, Takahashi K, Sakoda Y, et al
    Toll-like receptor 9 ligand D-type oligodeoxynucleotide D35 as a broad inhibitor for influenza A virus replication that is associated with suppression of neuraminidase activity.
    Antiviral Res. 2016 Feb 25. pii: S0166-3542(16)30089.
    PubMed     Text format     Abstract available


  61. CHERTOW DS, Kindrachuk J, Sheng ZM, Pujanauski LM, et al
    Influenza A and Methicillin-resistant Staphylococcus aureus Co-infection in Rhesus Macaques -- A Model of Severe Pneumonia.
    Antiviral Res. 2016 Feb 25. pii: S0166-3542(16)30098.
    PubMed     Text format     Abstract available


  62. MCKIMM-BRESCHKIN JL, Fry A
    Meeting report: 4 ISIRVAntiviral Group Conference: Novel Antiviral Therapies for Influenza and Other Respiratory Viruses.
    Antiviral Res. 2016 Feb 9. pii: S0166-3542(16)30015.
    PubMed     Text format     Abstract available


  63. SODERHOLM S, Anastasina M, Islam MM, Tynell J, et al
    Immuno-modulating properties of saliphenylhalamide, SNS-032, obatoclax, and gemcitabine.
    Antiviral Res. 2016;126:69-80.
    PubMed     Text format     Abstract available


  64. LYTRAS T, Kossyvakis A, Mentis A
    NAIplot: An opensource web tool to visualize neuraminidase inhibitor (NAI) phenotypic susceptibility results using kernel density plots.
    Antiviral Res. 2016;126:18-20.
    PubMed     Text format     Abstract available


  65. YANG JR, Chen CY, Kuo CY, Cheng CY, et al
    A novel H6N1 virus-like particle vaccine induces long-lasting cross-clade antibody immunity against human and avian H6N1 viruses.
    Antiviral Res. 2016;126:8-17.
    PubMed     Text format     Abstract available


    January 2016
  66. OKOMO-ADHIAMBO M, Mishin VP, Sleeman K, Saguar E, et al
    Standardizing the Influenza Neuraminidase Inhibition Assay among United States Public Health Laboratories Conducting Virological Surveillance.
    Antiviral Res. 2016 Jan 22. pii: S0166-3542(16)30011.
    PubMed     Text format     Abstract available


  67. YU J, Wang D, Jin J, Xu J, et al
    Antiviral activity of SA-2 against influenza A virus in vitro/vivo and its inhibition of RNA polymerase.
    Antiviral Res. 2016 Jan 20. pii: S0166-3542(16)30013.
    PubMed     Text format     Abstract available


  68. LIN C, Sun C, Liu X, Zhou Y, et al
    Design, synthesis, and in vitro biological evaluation of novel 6-methyl-7-substituted-7-deaza purine nucleoside analogs as anti-influenza A agents.
    Antiviral Res. 2016 Jan 20. pii: S0166-3542(16)30007.
    PubMed     Text format     Abstract available


  69. ZHOLOBAK NM, Mironenko AP, Shcherbakov AB, Shydlovska OA, et al
    Cerium dioxide nanoparticles increase immunogenicity of the influenza vaccine.
    Antiviral Res. 2016 Jan 5. pii: S0166-3542(15)30052.
    PubMed     Text format     Abstract available


  70. KIM Y, Kankanamalage AC, Damalanka VC, Weerawarna PM, et al
    Potent inhibition of enterovirus D68 and human rhinoviruses by dipeptidyl aldehydes and alpha-ketoamides.
    Antiviral Res. 2016;125:84-91.
    PubMed     Text format     Abstract available


  71. NORRIS MJ, Duan W, Cen Y, Moraes TJ, et al
    Agonistic 4-1BB antibody fails to reduce disease burden during acute respiratory syncytial virus (RSV) infection.
    Antiviral Res. 2016;125:46-50.
    PubMed     Text format     Abstract available


  72. GRANDIN C, Hourani ML, Janin YL, Dauzonne D, et al
    Respiratory syncytial virus infection in macaques is not suppressed by intranasal sprays of pyrimidine biosynthesis inhibitors.
    Antiviral Res. 2016;125:58-62.
    PubMed     Text format     Abstract available


    November 2015
  73. YUAN S, Chu H, Zhao H, Zhang K, et al
    Identification of a small-molecule inhibitor of influenza virus via disrupting the subunits interaction of the viral polymerase.
    Antiviral Res. 2015 Nov 21. pii: S0166-3542(15)30026.
    PubMed     Text format     Abstract available


    September 2015
  74. SHEPHARD A, Zybeshari S
    Virucidal action of sore throat lozenges against respiratory viruses parainfluenza type 3 and cytomegalovirus.
    Antiviral Res. 2015 Sep 22. pii: S0166-3542(15)00223.
    PubMed     Text format     Abstract available


  75. WEISS R, Laengle J, Sachet M, Shurygina AP, et al
    Interleukin-24 inhibits influenza A virus replication in vitro through induction of toll-like receptor 3 dependent apoptosis.
    Antiviral Res. 2015 Sep 11. pii: S0166-3542(15)00216.
    PubMed     Text format     Abstract available


  76. STRELTSOV VA, Pilling P, Barrett S, McKimm-Breschkin JL, et al
    Catalytic mechanism and novel receptor binding sites of human parainfluenza virus type 3 hemagglutinin-neuraminidase (hPIV3 HN).
    Antiviral Res. 2015 Sep 10. pii: S0166-3542(15)00209.
    PubMed     Text format     Abstract available


    August 2015
  77. LEE YN, Kim MC, Lee YT, Kim YJ, et al
    Co-immunization with tandem repeat heterologous M2 extracellular proteins overcomes strain-specific protection of split vaccine against influenza A virus.
    Antiviral Res. 2015 Aug 3. pii: S0166-3542(15)00174.
    PubMed     Text format     Abstract available


    June 2015
  78. YANG P, Li T, Liu N, Gu H, et al
    Recombinant influenza virus carrying human adenovirus epitopes elicits protective immunity in mice.
    Antiviral Res. 2015 Jun 23. pii: S0166-3542(15)00146.
    PubMed     Text format     Abstract available


  79. ZARUBAEV VV, Garshinina AV, Tretiak TS, Fedorova VA, et al
    Broad range of inhibiting action of novel camphor-based compound with anti-hemagglutinin activity against influenza viruses in vitro and in vivo.
    Antiviral Res. 2015 Jun 10. pii: S0166-3542(15)00135.
    PubMed     Text format     Abstract available


    May 2015
  80. PANOZZO J, Oh DY, Margo K, Morton DA, et al
    Evaluation of a dry powder delivery system for laninamivir in a ferret model of influenza infection.
    Antiviral Res. 2015;120:66-71.
    PubMed     Text format     Abstract available


  81. LIU R, An L, Liu G, Li X, et al
    Mouse lung slices: An ex vivo model for the evaluation of antiviral and anti-inflammatory agents against influenza viruses.
    Antiviral Res. 2015 May 26. pii: S0166-3542(15)00128.
    PubMed     Text format     Abstract available


  82. LU Y, Hardes K, Dahms SO, Bottcher-Friebertshauser E, et al
    Peptidomimetic furin inhibitor MI-701 in combination with oseltamivir and ribavirin efficiently blocks propagation of highly pathogenic avian influenza viruses and delays high level oseltamivir resistance in MDCK cells.
    Antiviral Res. 2015 May 25. pii: S0166-3542(15)00126.
    PubMed     Text format     Abstract available


  83. DABAGHIAN M, Latifi AM, Tebianian M, Dabaghian F, et al
    A truncated C-terminal fragment of Mycobacterium tuberculosis HSP70 enhances cell-mediated immune response and longevity of the total IgG to influenza A virus M2e protein in mice.
    Antiviral Res. 2015 May 16. pii: S0166-3542(15)00111.
    PubMed     Text format     Abstract available


  84. STOPPANI E, Bassi I, Dotti S, Lizier M, et al
    Expression of a single siRNA against a conserved region of NP gene strongly inhibits in vitro replication of different Influenza A virus strains of avian and swine origin.
    Antiviral Res. 2015 May 16. pii: S0166-3542(15)00110.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Influenza is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: